Using a new insight into the nature of ovarian cancer, a team of UC San Diego scientists have found potential new drug targets.
The researchers discovered that existing drugs targeting autophagy were effective in drug-resistant human tumors grafted onto mice, … Read more
Women who have a strong family history of breast or ovarian cancer are more likely to be affected by cancer of the ovaries, fallopian tube, or peritoneal cavity. This is thought to be due to a mutation in one of … Read more
By: Annette McElhiney
What lies ahead this year for health care and cancer care? I’m not a medical doctor, I’m just an 8½-year ovarian cancer survivor in remission. Who knows, the disease could come back 20 years later. So how … Read more
Ovarian cancer remains the most deadly gynecologic malignancy in the United States with more than 14,000 deaths in 2016. Yet, the prevalence remains low with approximately 22,000 cases in 2016. Stage at diagnosis is one of the strongest predictors of … Read more
By: Susan Gubar
Inside our new condo, the internet connection had failed. Two young men, sent by the cable company, had spent hours burying a cable to replace an antiquated line running into the building. As soon as they drove … Read more
Researchers from the Chinese Academy of Sciences have discovered that the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) helps cancer cells repair their DNA and found that inhibiting PGAM1 sensitizes tumors to the cancer drug Olaparib (Lynparza). Their findings in the … Read more
By: Cory Bentley, PhD
Many women diagnosed with ovarian cancer could probably write a dissertation for an advanced degree on ovarian cancer. Whether women are newly diagnosed or have recurrent ovarian cancer, the new learning needed to make informed decisions
Results from the Gynecologic Oncology Group (GOG) 252 trial, while highly anticipated in the oncology community, did not give any additional clarity for the use of intravenous (IV) versus intraperitoneal (IP) chemotherapy for patients with ovarian cancer, says Franco M. … Read more
Increasing the number of cycles of chemotherapy doesn’t appear to significantly influence recurrence rates or survival in patients with early stage ovarian clear cell carcinoma (OCCC), according to researchers.
The retrospective cohort study of 201 patients showed that recurrence and … Read more
Tesaro has opened an expanded access program (EAP) in the United States for their investigational poly ADP ribose polymerase (PARP) inhibitor, niraparib.
Now, niraparib is can be available, to treat a patient who meet certain criteria, with a serious disease … Read more
As we step into 2017, a big question looming in the minds of all stakeholders in the cancer research arena is: What is the future of cancer research in the new administration? Members of Congress on both sides of the … Read more
Fewer than half of women diagnosed with ovarian cancer live for five years or more. Sarah Adams, MD, a cancer doctor at the UNM Comprehensive Cancer Center, hopes a new therapy that delivers a one-two punch to cancer cells will … Read more
By: Annette McElhiney
Many of you have already read Dr. Maurie Markman’s article “In Ovarian Cancer Advancements, Finding New Biomarkers is Key” posted in the Clearity blog. It provoked me as an ovarian cancer survivor and non-medical professional … Read more
The search for validated, actionable biomarkers may be more important than initiating more phase 3 trials in the field of ovarian cancer, according to Maurie Markman, M.D.
“In the ovarian cancer arena, we have 30 years of history of doing … Read more
By: Helen Palmquist
In May 1987 when I was 41, I suddenly noticed my abdomen was getting large. I phoned my brother, an obstetrician and gynecologist, long distance to tell him I looked four or five months pregnant. He told … Read more
Testing for a gene commonly mutated in ovarian cancers could pick out patients who will respond well to a promising new class of cancer drugs, a major new study reveals.
Scientists found that defects in a gene called ARID1A caused … Read more
Heavily pre-treated patients with recurrent ovarian cancer have limited options when it comes to regimens that can control disease while maintaining a satisfactory quality of life.
Now, a phase II open-label study has demonstrated that a combination of the camptothecin … Read more
By: Annette McElhiney
Only a night from old to new!
Only a night, and so much wrought!
The Old Year’s heart all weary grew,
But said: The New Year rest has brought.”
The Old Year’s hopes its heart laid down,… Read more